Management of High Systolic Blood Pressure with Low Diastolic Blood Pressure

Initial Assessment

The European Society of Cardiology recommends confirming blood pressure measurements on separate occasions before initiating treatment, to ensure accurate diagnosis and appropriate management of patients with high systolic blood pressure and low diastolic blood pressure 4
Assessing for orthostatic hypotension before starting or intensifying treatment is crucial, especially in patients with wide pulse pressure, as recommended by the European Heart Journal 3
Evaluating cardiovascular disease risk is essential to guide treatment decisions for patients with high systolic blood pressure and low diastolic blood pressure, according to the European Heart Journal 3
Considering age, frailty status, and comorbidities when determining treatment targets is vital, as suggested by the European Heart Journal 2

The European Society of Cardiology recommends targeting systolic blood pressure to 120-129 mmHg for most adults to reduce cardiovascular disease risk, if well tolerated, with a strength of evidence rated as high 2
Considering more lenient systolic blood pressure targets (<140 mmHg) for patients with pre-treatment symptomatic orthostatic hypotension, age ≥85 years, moderate to severe frailty, or limited life expectancy (<3 years) is recommended by the European Heart Journal 2
Targeting diastolic blood pressure to <80 mmHg for all hypertensive patients is suggested by the European Heart Journal, with a strength of evidence rated as moderate 2
When systolic blood pressure is at target (120-129 mmHg) but diastolic blood pressure remains ≥80 mmHg, considering further lowering diastolic blood pressure to 70-79 mmHg if tolerated is recommended by the European Heart Journal, with a strength of evidence rated as low 2

Implementing lifestyle changes, such as weight loss, adopting a DASH or Mediterranean dietary pattern, and regular physical activity, is recommended for all patients with elevated blood pressure (>120/80 mmHg) by the American Heart Association, with a strength of evidence rated as high 4
Recommending weight loss if overweight/obese, aiming for BMI 20-25 kg/m², is suggested by the European Heart Journal, with a strength of evidence rated as moderate 2
Encouraging regular physical activity, such as 150 min/week moderate-intensity or 75 min/week vigorous aerobic exercise plus resistance training 2-3 times/week, is recommended by the European Heart Journal, with a strength of evidence rated as high 2

Initiating combination therapy with a RAS blocker (ACE inhibitor or ARB) plus either a dihydropyridine CCB or thiazide/thiazide-like diuretic for confirmed hypertension (≥140/90 mmHg) is recommended by the European Heart Journal, with a strength of evidence rated as high 3
Using single-pill combinations when possible to improve adherence is suggested by the European Heart Journal, with a strength of evidence rated as moderate 3
Considering starting with lower doses to avoid excessive diastolic blood pressure reduction in patients with high systolic blood pressure but low diastolic blood pressure (wide pulse pressure) is recommended by the European Heart Journal, with a strength of evidence rated as low 1

Monitoring for symptoms of hypoperfusion (dizziness, falls, confusion) when diastolic blood pressure is already low is crucial, as recommended by the European Heart Journal, with a strength of evidence rated as high 2
Considering administering one or more antihypertensive medications at bedtime to reduce nocturnal blood pressure and cardiovascular events is suggested by the American Heart Association, with a strength of evidence rated as moderate 5
Titrating medications more gradually than usual, with more frequent follow-up, is recommended for patients with wide pulse pressure, as suggested by the European Heart Journal, with a strength of evidence rated as low 3

Scheduling more frequent follow-up visits during treatment initiation and titration is recommended by the American Heart Association, with a strength of evidence rated as high 6
Using appointment reminders and following up with patients who miss appointments is suggested by the American Heart Association, with a strength of evidence rated as moderate 6
Simplifying medication regimens to once-daily dosing when possible is recommended by the American Heart Association, with a strength of evidence rated as high 6
Collaborating with other healthcare professionals (nurses, pharmacists, dietitians) is essential for improving patient outcomes, as suggested by the American Heart Association, with a strength of evidence rated as moderate 6

Avoiding aggressive blood pressure lowering in patients with already low diastolic blood pressure (<60 mmHg) is crucial, as recommended by the European Heart Journal, with a strength of evidence rated as high 2
Delaying combination therapy in patients with confirmed hypertension ≥140/90 mmHg is not recommended, as suggested by the European Heart Journal, with a strength of evidence rated as moderate 3
Using monotherapy when combination therapy would be more effective is not recommended, as suggested by the European Heart Journal, with a strength of evidence rated as moderate 3
Combining two RAS blockers (ACE inhibitor and ARB) is not recommended, as suggested by the European Heart Journal, with a strength of evidence rated as high 3
Discontinuing treatment prematurely is not recommended, as blood pressure-lowering treatment should be maintained lifelong if tolerated, as suggested by the European Heart Journal, with a strength of evidence rated as high 3